最新 100 件のみ表示中(全 3852 件)。 古い論文は Knowledge/ の MOC / Entity ページから辿れます。

2026-07-02 (5 papers)

2026-07-01 (2 papers)

  • Tian et al. NatBiomedEng 2026 — Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for duchenne muscular dystrophy (Basic-Extracellular vesicles)
  • Goto et al. Nature 2024 — SOX17 enables immune evasion of early colorectal adenomas and cancers (Basic-Others)

2026-06-30 (9 papers)

  • Li et al. CancerImmunolRes 2026 — Peripheral th17 immune signature associates with excellent response to anti-PD1anti-PD-L1 therapy across solid tumors (Basic-Others)
  • Borghaei et al. ClinCancerRes 2026 — Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small … (Clinical-NSCLC-Driver negative)
  • Okamoto et al. LungCancer 2026 — Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC an… (Clinical-NSCLC-EGFR)
  • Itchins et al. LungCancer 2026 — Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from t… (Clinical-NSCLC-ROS1)
  • Abrahimi et al. JExpMed 2026 — Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models (Clinical-Novel modalities)
  • Hofman et al. LungCancer 2026 — New biomarkers for antibody-drug conjugates in lung cancer the pathologist’s perspective (Clinical-Novel modalities)
  • Cowzer et al. ClinCancerRes 2026 — Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer (Clinical-Others)
  • Medina et al. ClinCancerRes 2026 — AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A… (Clinical-Others)
  • Mahmud et al. Oncologist 2026 — Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer… (Clinical-Others)

2026-06-28 (11 papers)

2026-06-27 (19 papers)

  • Zhu et al. JImmunotherCancer 2026 — Spatial immune atlas of breast cancer brain metastasis reveals CD163+ macrophage reprogramming associated with immune… (Basic-Brain metastasis)
  • Wen et al. NatBiotechnol 2026 — Spatially resolved profiling of extracellular vesicles in tissues with spatial-EV-seq (Basic-Extracellular vesicles)
  • George et al. CancerRes 2026 — Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8… (Basic-Immunotherapy)
  • Wu et al. JImmunotherCancer 2026 — Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39+ CD8+ T cells highlights imm… (Basic-Immunotherapy)
  • Scaparone et al. CancerDiscov 2026 — EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling throug… (Basic-Oncogene and genetics)
  • Gu et al. CancerRes 2026 — EGFR N-glycosylation catalyzed by NDST2 promotes lenvatinib resistance in hepatocellular carcinoma (Basic-Oncogene and genetics)
  • Clarke et al. CancerRes 2026 — Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer (Basic-Others)
  • Jiang et al. Cancers 2026 — Selective Inhibition of KRAS G13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Ca… (Basic-Others)
  • Repetto et al. ClinCancerRes 2026 — The genomic landscape of MYC, MYCL, and MYCN amplified solid tumors (Basic-Others)
  • Abascal et al. JImmunotherCancer 2026 — FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-… (Basic-Others)
  • De et al. NatMed 2026 — Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+/HER2- breast cancer: a randomize… (Basic-Others)
  • Bashir et al. CancerCell 2026 — Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth (Basic-Tumor microenvironment)
  • Liu et al. CancerCell 2026 — Molecular phenotypes and spatial archetypes A new framework for cancer-associated fibroblasts (Basic-Tumor microenvironment)
  • Vujanovic et al. ClinCancerRes 2026 — Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with… (Clinical-NSCLC-Driver negative)
  • Zamulko et al. ClinCancerRes 2026 — A phase 2 feasibility study combining pembrolizumab and metformin in patients with metastatic head and neck cancer (Clinical-NSCLC-Driver negative)
  • Amor et al. Cell 2026 — CAR T targets AI takes the wheel (Clinical-Novel modalities)
  • Baker et al. Cell 2026 — AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy (Clinical-Novel modalities)
  • Li et al. MolCancer 2026 — Antibody-drug conjugates in breast cancer from mechanism to revolutionizing clinical practice (Clinical-Novel modalities)
  • Trotta et al. Cell 2026 — Excessive vascular integrity restricts anti-tumor immunity (Clinical-SCLC)

2026-06-25 (17 papers)

  • Wang et al. IntJBiolSci 2026 — USP33 Promotes Lung Adenocarcinoma Brain Metastasis by Inhibiting the K48-Linked Ubiquitination and Degradation of S1… (Basic-Brain metastasis)
  • Cai et al. MolCancer 2026 — Extracellular vesicles in solid tumors from tumor ecology to engineered therapeutics (Basic-Extracellular vesicles) review
  • Cai et al. JImmunotherCancer 2026 — Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multi… (Basic-Liquid-biopsy)
  • Horndalsveen et al. JThoracOncol 2026 — ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab (Basic-Liquid-biopsy)
  • Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer (Basic-Others) review
  • Marinello et al. CancerDiscov 2026 — Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer (Basic-Others)
  • Zhu et al. CancerMed 2026 — Harnessing gut microbiota to enhance immunotherapy in NSCLC from mechanisms to translational applications (Basic-Others) review
  • Zhang et al. JImmunotherCancer 2026 — HDAC inhibitors reverse YAP-driven immune resistance in NSCLC mechanistic and translational evidence (Basic-Others)
  • Zhang et al. Nature 2026 — The mutational landscape of STING-induced immunity (Basic-Others)
  • Chien et al. CancerImmunolImmunother 2026 — Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lun… (Clinical-NSCLC-Driver negative)
  • Ulas et al. JImmunotherCancer 2026 — Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Patients with Metastatic NSCLC: The … (Clinical-NSCLC-Driver negative)
  • Lu et al. ClinLungCancer 2026 — Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advan… (Clinical-NSCLC-EGFR)
  • Garrido-Castro et al. AnnOncol 2026 — SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with meta… (Clinical-Novel modalities)
  • Jee et al. CancerDiscov 2026 — Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival (Clinical-Novel modalities)
  • Rohrberg et al. JImmunotherCancer 2026 — First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic so… (Clinical-Others)
  • Roulleaux-Dugage et al. JImmunotherCancer 2026 — VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC (Clinical-Others)
  • Zhang et al. FrontImmunol 2026 — First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain meta… (Clinical-SCLC)

2026-06-24 (1 papers)

2026-06-22 (3 papers)

2026-06-21 (15 papers)

2026-06-20 (10 papers)

  • Walther et al. JExtracellVesicles 2026 — Therapeutic poxviruses induce the secretion of immunostimulating and anti-tumoral extracellular vesicles (Basic-Extracellular vesicles)
  • Lin et al. JImmunotherCancer 2026 — Integrin CD11b/CD18 Reprograms Macrophage Polarization by Suppressing ERK/STAT3 Signaling to Enhance Antitumor Immuni… (Basic-Neutrophil and myeloid cell)
  • Liao et al. CancerCell 2026 — Targeting TROP2 in Drug-Tolerant Persister Cells Delays EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell L… (Basic-Oncogene and genetics)
  • Gan et al. AdvSci 2026 — Single-Cell Reveal GALNT7-Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non-Small C… (Basic-Others)
  • Muneer et al. CancerLett 2026 — Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center … (Basic-Others)
  • Strohbehn et al. JCOOncolPract 2026 — Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted … (Basic-Others)
  • Dymun et al. SciTranslMed 2026 — Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous trans… (Basic-Others)
  • Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer followi… (Clinical-NSCLC-EGFR) review
  • Li et al. FrontImmunol 2026 — Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer… (Clinical-Others) review
  • Lovly et al. JCOPrecisOncol 2026 — Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non–Small C… (Clinical-Others)

2026-06-19 (8 papers)